Archive For: Conference

Poster presentation at PAGE 2018

Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood. Link to abstract

M. Machacek (1), L. Renaud (1), C. Kohl (2), M. Vercauteren (2), L. Remen (2), R. Welford (2). (1) LYO-X GmbH, Ringstrasse 9, 4123 Allschwil, Switzerland. (2) Idorsia Pharmaceuticals Limited, Hegenheimermattweg 91, 4123 Allschwil, Switzerland… Read the rest “Poster presentation at PAGE 2018”


12th Basel M&S Seminar: ‘Modelling … AND SIMULATION’

Read the rest “12th Basel M&S Seminar: ‘Modelling … AND SIMULATION’”


ASCO 2016 abstract 2

Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, Oswald Burkhard, Victor Rodriguez Laval, Glyn Steventon, Nalan Utku, Holger Jansen; LYO-X GmbH, Allschwil, Switzerland; Department of Internal Medicine, Charité-Universitätsmedizin, Berlin, Germany; Department for Hemato-Oncology, Comprehensive Cancer Center, Charité-University Medicine, Berlin, Germany; Medizinischen Klinik m.S. Hepatologie und Gastroenterologie, Berlin, Georgia; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; Hannover Medical School, Hannover, Germany; Onkologie Praxis, Leer, Germany; Klinikum Ludwigsburg, Ludwigsburg, Germany; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany; Onkologie Praxis, Worms, Germany; Instutut für Radiologie, Berlin, Germany; University of Surrey, Surrey, United Kingdom; CellAct, Dortmund, Germany; CellAct Pharma GmbH, Dortmund, Germany. … Read the rest “ASCO 2016 abstract 2”


ASCO 2016 abstract 1

Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. Matthias Machacek1, Lionel Renaud1, Sasa Dimitrijevic2, Debora Schmitz2, Elena Ivanova2, Karin Jorga3; 1LYO-X GmbH, Allschwil, Switzerland; 2PIQUR Therapeutics AG, Basel, Switzerland; 3Karin Jorga Life Science Consulting GmbH, Basel, Switzerland. J Clin Oncol 34, 2016 (suppl; abstr e14101).… Read the rest “ASCO 2016 abstract 1”


LATSIS Symposium ETH ZURICH on Personalised Medicine

LYO-X is sponsoring the LATSIS Symposium on Personalised Medicine to be held at the ETH Zurich June 27–29 2016. Personalised medicine has a number of quite attractive advantages. Treatments tailored to the individual patient, for example by therapy selection based on diagnostic tools or by individualised dosing, should improve the effect, lower side effects and lower costs by avoiding ineffective treatments. It appears to be an obvious solution given the situation we have today in the health care system. However, despite the advantages most drugs are still developed as a one-fits-all solution without any diagnostic tools.… Read the rest “LATSIS Symposium ETH ZURICH on Personalised Medicine”


20. PK/PD Expert Meeting

We were very kindly invited to the 20. Pharmacokinetics/Pharmacodynamics Expert Meeting in Berlin April 14th – 16th 2016. It will be a great opportunity to meet the German PKPD experts. There is an attractive agenda including:

  • Systems Pharmacology
    Methods, Applications, Opportunities and Challenges
  • Dose Finding in Phase II for Confirmatory Clinical Trials
    Overview, Methods, Good Practices and Examples
  • PK/PD of Locally Applied Drugs
    Considerations for (Sub-)Cutaneous and Ocular Administration of Pharmaceuticals

Of course we are in the Systems Pharmacology session where we will talk about the “Introduction to Concepts and Methods of Systems Pharmacology”.… Read the rest “20. PK/PD Expert Meeting”



We will be at ACoP6 with our partner Lixoft meeting the pharmacometrics community and teaching at the Monolix Suite workshop.
I’m looking very much forward to the event. It will be great to meet all my friends and colleagues especially everyone living in the US who I have not seen for quite a while.
I’m going to talk about Simulx on day two of the Monolix Suite workshop which I’m especially proud of. It is such an elegant and powerful solution for NLME simulations.… Read the rest “ACoP6”


Why Investing Millions in Generating Data?

LYO-X will be at the Life Science Forum Basel this coming Thursday, June 18th. We will address the very relevant question “Why Investing Millions in Generating Data?” and show “How to Use Systems Pharmacology to Make the Most of Your Data”. Join us at this event with a very exciting program. The event is at the Pharmazentrum/Biozentrum of the University of Base and starts midday. For more details see the PROGRAM.… Read the rest “Why Investing Millions in Generating Data?”


Fighting Ebola Disease

LYO-X is helping to determine the optimal dose of ZMapp™, a monoclonal antibody cocktail, for the treatment of Ebola virus disease. This project shows another reason why it is critical to determine the right dose. With no approved vaccine or medicine the sudden outbreak of Ebola virus disease in February 2014 caught the world off guard.  Optimal dosing in such circumstances is not only a matter of safety and efficacy but also of providing treatment to every patient in need. Modelling approaches can help in such situations to integrate sparse data to inform the right dose or to put forward hypotheses that can be tested in a targeted way to derive better information on the right dose and regimen.… Read the rest “Fighting Ebola Disease”